Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Stromedix licenses Biogen Idec's MAb for transplant

Executive Summary

Stromedix (fibrosis drug start-up) has licensed from Biogen Idec STX100, a humanized MAb known to inhibit the activation of transforming growth factor (TGF)-beta, a key player in a variety of pathologies including fibrosis and oncology. Biogen Idec will take an undisclosed equity position in Stromedix.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies